Stock info Johnson & Johnson | Filter  Basic-Info

Stock: Johnson & Johnson (US large caps), ISIN: US4781601046

Last Price 143.85 Max Price 166.99
Min Price 143.85 1 Year return -18.57
Sector Health Care Subsector Pharmaceuticals
Annual report 2020


Johnson & Johnson
Johnson & Johnson is the global leading firm for carrying out the processes of manufacturing and sales of medical, health care, and pharmaceutical products for consumers and to fulfill the needs of research and developmental activities on a broader range of health care fields. The company has been founded back to the year in 1886 by Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson and has been head-quartered in New Brunswick, New Jersey and the consumer-division is being headed in Skillman, New Jersey. The company has been assisted with the help of around 250 auxiliary units which operates in about 57 of the countries worldwide and the selling of its productions is being done in 175 of the countries. In the year of 2011, this company had acquired a sales reach up to 65 Billion $ in the field of pharmaceuticals and is now trade with the help of the New York Stock Exchange and is one of the main component of Dow Jones Industrial Average and also of S&P 500 Component. Fortune 500 has also given the space to Johnson & Johnson in its listings along with the top rank of Harris Interactive National Corporate Reputation Survey and the tag of ‘world's most respected company’ by Barron’s Magazine and at last had been given the award of Benjamin Franklin for the ‘Public Diplomacy by the U.S. State Department’, the first award given to any of the Corporation.
ALZA Corporation, LifeScan, Inc., McNeil Nutritionals, Biosense Webster, Inc., Cilag, Cordis Corporation, Janssen Pharmaceutica, Penaten, Tibotec and many more names are included in the list of the auxiliaries of this company. And for naming the brands acquired by this company, there are also a fewer examples starting from the house-hold name for medical and first-aid purpose products i.e. BandAid, Tylenol, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash, Acuvue, Cortef, Reactine, Motrin, Benadryl, Calprofen, Simponi, and the list is not completed yet.
 
There are three of the main division that have been made by this company and those includes Consumer, Pharmaceutical and Medical Devices & Diagnostics. Consumer division take care of broader ranges of consumer-health and personal-care productions that may be of baby, beauty, oral-care, women health category or related to nutrition. Pharmaceutical division is for focusing of medical needs that have not been fulfilled yet including the therapeutical treatment of immunology,  neuro-science, cardio-vascular, oncology or that of metabolism. Medical Devices & Diagnostics divisions go for broader ranges of services and products with the distribution to the whole-salers, retailing entities, hospitals, clinics and other diagnostic labs where these products are used for the researches and treatments by physician, nurses and therapists. The main focus of this section includes the cardio-vascular diseases, diabetic care, visionary care, wound-care, preventing of infectious materials, invasive surgeries (minimal type) and for diagnosis.

Loading...

Contact info:Street: One Johnson & Johnson PlazaZip Code: P.O. Box 767Postbox: New Jersey 08933City: MilwaukeeCountry: USAPhone: (732) 524-0400Website: www.jnj.comCEO: Alex Gorsky

Sector Review Johnson & Johnson

Loading...
Year Turnover Total sector Market share
2019 82,059 615,670 13.33 %
2020 82,584 638,104 12.94 %
2021 93,775 727,997 12.88 %
2022 94,943 787,317 12.06 %
2023 0 0 0.00 %

Advice Johnson & Johnson

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
February 09, 2023 Beleggers Belangen Johnson & Johnson Buy
November 15, 2021 ABN AMRO Johnson & Johnson Buy
June 04, 2021 Credit Suisse Johnson & Johnson Buy 193.00 7.60 %
March 02, 2021 ABN AMRO Johnson & Johnson Hold
January 26, 2021 KBC Securities Johnson & Johnson Hold 160.00 -11.46 %
July 17, 2020 Credit Suisse Johnson & Johnson Buy 163.00 -4.14 %
July 17, 2020 Citigroup Johnson & Johnson Buy 170.00 -4.91 %
July 17, 2020 KBC Securities Johnson & Johnson Hold 150.00 -13.17 %
July 17, 2020 ABN AMRO Johnson & Johnson Hold
July 06, 2020 ABN AMRO Johnson & Johnson Hold 141.00 -19.84 %
April 24, 2020 Independent Research Johnson & Johnson Hold 161.00 -10.77 %
April 15, 2020 Citigroup Johnson & Johnson Buy 165.00 3.35 %
April 10, 2020 Raymond James Johnson & Johnson Buy 153.00 -16.56 %
April 02, 2020 Wells Fargo Johnson & Johnson Buy 150.00 -18.89 %
April 02, 2020 Stifel Johnson & Johnson Hold 140.00 -27.39 %
March 02, 2020 Independent Research Johnson & Johnson Hold 159.00 0.34 %
January 24, 2020 Independent Research Johnson & Johnson Hold 161.00 -0.45 %
January 24, 2020 Raymond James Johnson & Johnson Buy 161.00 -0.45 %
January 09, 2020 JP Morgan Johnson & Johnson Hold 150.00 -18.89 %
December 17, 2019 Morgan Stanley Johnson & Johnson Buy 170.00 -4.91 %
October 23, 2019 Independent Research Johnson & Johnson Hold 140.00 -2.81 %
October 16, 2019 Independent Research Johnson & Johnson Hold 148.00 -0.24 %
October 16, 2019 Raymond James Johnson & Johnson Buy 147.00 -0.93 %
October 16, 2019 Credit Suisse Johnson & Johnson Buy 158.00 6.10 %
August 29, 2019 Credit Suisse Johnson & Johnson Buy 156.00 2.35 %
July 26, 2019 Citigroup Johnson & Johnson Buy 143.00 -3.29 %
July 17, 2019 JP Morgan Johnson & Johnson Hold 146.00 -2.36 %
July 16, 2019 KBC Securities Johnson & Johnson Hold 140.00 -6.75 %
April 17, 2019 Credit Suisse Johnson & Johnson Hold 152.00 2.86 %
April 16, 2019 KBC Securities Johnson & Johnson Hold 140.00 -4.31 %
March 06, 2019 Independent Research Johnson & Johnson Hold 143.00 -0.34 %
January 29, 2019 Credit Suisse Johnson & Johnson Hold 151.00 1.49 %
January 23, 2019 Barclays Johnson & Johnson Hold 135.00 -32.10 %
January 02, 2019 Morgan Stanley Johnson & Johnson Hold 130.00 -11.77 %
January 02, 2019 Citigroup Johnson & Johnson Buy 139.00 -4.53 %
December 21, 2018 Independent Research Johnson & Johnson Hold 135.00 -8.19 %
December 14, 2018 Credit Suisse Johnson & Johnson Hold 153.00 7.71 %
October 17, 2018 Credit Suisse Johnson & Johnson Hold 152.00 14.00 %
October 12, 2018 Morgan Stanley Johnson & Johnson Hold 153.00 13.81 %
July 13, 2018 Jefferies & Co. Johnson & Johnson Buy 145.00 -22.99 %



News Johnson & Johnson

2023 record year for Johnson & Johnson

Tomorrow the American Johnson & Johnson will report its past quarters results. For this year Johnson & Johnson 's revenue will be around 97.71 billion USD. This is according to the average of the analysts' estimates. The expected revenue would be arecord...

Johnson & Johnson given go-ahead for bankruptcy strategy on talc lawsuits

. A bankruptcy court judge has upheld Johnson & Johnson 's request to use a bankruptcy strategy to handle 38K lawsuits related to its talc products pending against the company, The Wall Street Journal reports. The ruling by Judge Michael Kaplan ofthe...

Johnson & Johnson unit, SRI International to collaborate on drug discovery using AI

Johnson & Johnson's (NYSE:JNJ) Janssen unit will collaborate with SRI International using the latter's artificial intelligence ("AI") guided, automated synthetic-chemistry system to discover small molecule drugs. The companies say...

J&J Janssen unit, SRI International to collaborate on drug discovery using AI

Johnson & Johnson 's (NYSE:JNJ) Janssen unit will collaborate with SRI International using the latter's artificial intelligence ("AI") guided, automated synthetic-chemistry system to discover small molecule drugs. The companies say the SynFini platform...

J&J expects to file for 14 new drugs by 2025

Johnson & Johnson (JNJ) intends to file applications for 14 new drugs by 2025, with average peak sales of $4B for each of them, a company executive tells Reuters. Among the top programs, Janssen Pharmaceutical Global Head of Research Mathai Mammenhighlighted...

Annual reports Johnson & Johnson

2017 2018 2019 2020 2021

Profile Johnson & Johnson

Johnson & Johnson

(US4781601046)/ JNJ

Johnson & Johnson's main office is based in Milwaukee. The company mostly operates in the health care eq. & services sector. Alex Gorsky is the company' CEO. Over the past 10 years the global health care companies gained around 102 percent. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-2016) there is a plus of 102 percent.

The past year was a relatively good year for Johnson & Johnson investors

The period between December 2015 and December 2016 was a profitable period for the investors in Johnson & Johnson. The stock gained around 13 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 77 percent. Johnson & Johnson's revenues between 2011 and 2015 were relatively stable and moved between 41,96 billion dollars and 37,18 billion dollars. Johnson & Johnson's net incomes between 2011 and 2015 were quiet stable and moved between 1,74 billion dollars and 1,55 billion dollars.

Johnson & Johnson paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 4,04 percent. Over the past 5 years Johnson & Johnson raised her dividends share each year. Because of the yearly increased dividends Johnson & Johnson can be called a kind of dividend aristocrat.

At the end of 2015 around 126,5 thousand people were employed at Johnson & Johnson.

Healthy financed: not so much debt Johnson & Johnson

As per the end of 2015 the American company's balance sheet equaled 29,67 billion dollars. The total debt was around 19,3 billion dollars. This is 65,03 percent of the total balance sheet. The American company's price/earnings-ratio was 18. So the market valued the stock at 18 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the health care company's market capitalization (the number of shares times the market price) equaled around 64,87 billion dollars. At the end of 2015 the American company had around 647,37 million stocks listed.

All the annual reports of Johnson & Johnson are available here. More information about Johnson & Johnson can be found it's website. .


Results Johnson & Johnson

Results
2015
2016
2017
2018
2019
2020
Revenue
70,074
71,890
76,450
81,581
82,059
82,584
Costs
54,665
55,350
75,150
66,284
66,940
67,870
Profit
15,409
16,540
1,300
15,297
15,119
14,714
Margin of profit
21.99
23.01
1.70
18.75
18.42
17.82
ROI
21.66
23.49
2.16
25.60
25.42
23.25

Balance Johnson & Johnson

Balance
2015
2016
2017
2018
2019
2020
Equity
71,150
70,418
60,160
59,752
59,471
63,278
Debt
62,261
70,790
97,143
93,202
98,257
111,616
Total assets
133,411
141,208
157,303
152,954
157,728
174,894
Solvency
53.33
49.87
38.24
39.07
37.70
36.18
Cash
38,376
41,907
18,296
19,687
19,287
25,185
Cashflow
19,569
18,767
21,056
22,201
23,416
23,536
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.31
0.27
0.22
0.24
0.24
0.21

Details Johnson & Johnson

Details
2016
2017
2018
2019
2020
Price
102.72
115.21
139.72
129.05
145.87
Eps
5.93
0.47
5.61
5.63
5.51
Price/earnings-ratio
17.32
245.13
24.91
22.92
26.11
Dividend
3.15
3.32
3.54
3.75
3.98
Dividend %
3.07 %
2.88 %
2.53 %
2.91 %
2.77 %
Payout %
0.53
7.06
0.63
0.67
0.72
Book value
26.02
22.43
22.44
22.59
24.04
Market to book
0.25
0.19
0.16
0.18
0.17
Cashflow per stock
6.93
7.85
8.34
8.89
8.94
Stocks
2,707
2,683
2,662
2,633
2,633
Market Cap
278.012.81
309.053.71
371.979.35
339.725.42
378.686.56

Dividend Johnson & Johnson


Price info Johnson & Johnson

Date
Price
17 Dec 2024
143.85
10 Dec 2024
149.60
06 Dec 2024
149.52
03 Dec 2024
154.80
29 Nov 2024
155.40
27 Nov 2024
154.52
13 Nov 2024
152.64
08 Nov 2024
156.73
05 Nov 2024
158.24
31 Oct 2024
160.61
29 Oct 2024
161.60
23 Oct 2024
163.45
19 Oct 2024
165.12
16 Oct 2024
164.10
14 Oct 2024
161.46
05 Oct 2024
160.29
02 Oct 2024
161.99
27 Sep 2024
161.39
20 Sep 2024
164.82
17 Sep 2024
166.99
13 Sep 2024
164.64
28 Aug 2024
162.95
26 Aug 2024
164.13
23 Aug 2024
162.35
11 Aug 2024
160.62
07 Aug 2024
158.90
05 Aug 2024
164.14
01 Aug 2024
157.85
30 Jul 2024
158.56
26 Jul 2024
159.64